55
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Novel Methods in Vascular and Lymphatic Physiology

      Submit here by June 30, 2025

      About Journal of Vascular Research: 1.8 Impact Factor I 3.4 CiteScore I 0.486 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Which Features of the Metabolic Syndrome Predict the Prevalence and Clinical Outcomes of Angiographic Coronary Artery Disease?

      review-article

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: The prevalence of the metabolic syndrome (MS) is growing. The Adult Treatment Panel (ATP) III provided a uniform definition of MS but no information on its predictive ability. Methods: We tested the ability of MS and its components to predict angiographic coronary artery disease (CAD) and incident death/myocardial infarction (D/MI) over 2.8 ± 2.3 years in a large cohort of patients undergoing angiography. ATP-III criteria were used for fasting glucose (FG), triglyceride (TG), high-density lipoprotein cholesterol (HDL), and blood pressure (BP); body mass index (BMI) >27 kg/m<sup>2</sup> was used as a surrogate for waist circumference. Results: 3,128 subjects were studied; 65% had advanced CAD (≧70% stenosis), and 35%, no CAD. MS was present in 64% (high FG 40%; high TG 52%; low HDL 71%; high BP 76%; high BMI 58%). Presence of CAD was predicted by MS [adjusted odds ratio (OR) = 1.30, 95% CI 1.10–1.55, p = 0.003] and, individually, by high FG (OR = 1.90, CI 1.63–2.23) and low HDL (OR = 1.38, CI 1.18–1.62). In multivariable modeling, CAD was predicted by high FG (OR = 1.80, CI 1.51–2.16) and low HDL (OR = 1.57, CI 1.31–1.89) as well as by age, gender, family history, smoking, and LDL cholesterol (all p < 0.001). For secondary risk of incident D/MI, only high FG of MS features was predictive (adjusted hazard ratio 1.46, CI 1.17–1.82, p = 0.001), and this risk was carried by diabetes (adjusted hazard ratio 1.71, p < 0.001); other predictors were age, heart failure, revascularization strategy, renal insufficiency, prior MI, and number of diseased vessels. Conclusion: MS has primary predictive ability for CAD, carried primarily by high FG and low HDL. Secondary predictive ability of MS features for clinical outcomes, in the setting of established CAD, is carried by diabetes alone. Dysglycemia deserves specific attention as a target for prevention and treatment.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          0008-6312
          1421-9751
          2004
          February 2004
          27 February 2004
          : 101
          : 4
          : 185-193
          Affiliations
          Cardiovascular Department, LDS Hospital and University of Utah, Salt Lake City, Utah, USA
          Article
          76695 Cardiology 2004;101:185–193
          10.1159/000076695
          14967961
          f709ae8f-2de9-4e65-bcff-05850d3ea2d9
          © 2004 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 02 October 2003
          : 20 October 2003
          Page count
          Figures: 6, Tables: 4, References: 42, Pages: 9
          Categories
          General Cardiology

          General medicine,Neurology,Cardiovascular Medicine,Internal medicine,Nephrology
          Coronary artery disease,Prevention,Diabetes,Metabolic syndrome,Risk

          Comments

          Comment on this article

          Related Documents Log